var data={"title":"Metronidazole (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Metronidazole (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390030?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=metronidazole-systemic-drug-information\" class=\"drug drug_general\">see &quot;Metronidazole (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=metronidazole-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Metronidazole (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770965\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Carcinogenic: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Metronidazole has been shown to be carcinogenic in mice and rats. Unnecessary use of the drug should be avoided. Its use should be reserved for the conditions for which this drug is indicated.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770969\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>First-Metronidazole 100;</li>\n      <li>First-Metronidazole 50;</li>\n      <li>Flagyl;</li>\n      <li>Flagyl ER [DSC];</li>\n      <li>Metro;</li>\n      <li>MetroNIDAZOLE Benzo+SyrSpend</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770970\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Flagyl</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10529895\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Amebicide</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Anaerobic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiprotozoal</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443888\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection:</b> Limited data available; dosing regimens variable:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Weight-directed dosing (Bradley 2017): IV, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 15 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Body Weight</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Postnatal Age</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Dose</b></p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;text-align:center;\">&le;2 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;28 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">29 to 60 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;2 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;8 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 mg/kg/dose every 8 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:4em;\">Age-directed dosing (Cohen-Wolkowiez 2012; Cohen-Wolkowiez 2013): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 15 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Postmenstrual age (PMA)</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Dose</b></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;34 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">34 to 40 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;40 weeks</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5 mg/kg/dose every 6 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical prophylaxis</b> (IDSA/ASHP [Bratzler] 2013): Limited data available: IV:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Body Weight</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Dose</b></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;1.2 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5 mg/kg as a single dose 30 to 60 minutes prior to procedure</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;1.2 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 mg/kg as a single dose 30 to 60 minutes prior to procedure</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10529964\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=metronidazole-systemic-drug-information\" class=\"drug drug_general\">see &quot;Metronidazole (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Some clinicians recommend using adjusted body weight in obese children. Dosing weight = IBW + 0.45 (TBW-IBW)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP 2015]): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 30 to 50 mg/kg/<b>day</b> in divided doses 3 times daily; maximum daily dose: 2,250 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 22.5 to 40 mg/kg/<b>day</b> in divided doses 3 times daily; maximum daily dose: 1,500 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Amebiasis:</b> Infants, Children, and Adolescents: Oral: 35 to 50 mg/kg/<b>day</b> in divided doses every 8 hours for 7 to 10 days; maximum dose: 750 mg/dose; for severe infection or extraintestinal disease, IV may be necessary (Bradley 2017; Drugs for Parasitic Infections 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Appendicitis, perforated (divided dosing):</b> Children and Adolescents: IV: 30 mg/kg/<b>day</b> in divided doses 3 times daily (Emil 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Appendicitis, perforated (once-daily dosing):</b> Limited data available: Children and Adolescents: IV: 30 mg/kg/dose once daily in combination with ceftriaxone; maximum reported daily dose: 1,500 mg/<b>day</b> (Yardeni 2013); however, other pediatric trials did not report a maximum; in adult patients, a maximum daily dose of 1,500 mg/day for once-daily dosing is suggested (Solomokin 2010); in pediatric patients, once-daily metronidazole in combination with ceftriaxone has been shown to have similar efficacy as triple-combination therapy with ampicillin, clindamycin, and gentamicin (Fraser 2010; St Peter 2006; St Peter 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Balantidiasis:</b> Infants, Children, and Adolescents: Oral: 35 to 50 mg/kg/<b>day</b> in divided doses every 8 hours for 5 days; maximum dose: 750 mg/dose (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter (peritoneal dialysis); exit-site or tunnel infection:</b> Infants, Children, and Adolescents: Oral: 10 mg/kg/dose 3 times daily. Maximum dose: 500 mg/dose (ISPD [Warady 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Clostridium difficile</i></b>\n      <b> diarrhea:</b> Infants, Children, and Adolescents: Oral: 30 mg/kg/<b>day</b> in divided doses 4 times daily for at least 10 days; maximum daily dose: 2,000 mg/<b>day</b> (<i>Red Book</i> [AAP 2015]; AAP [Schutze 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Dientamoeba fragilis:</i></b> Infants, Children, and Adolescents: Oral: 35 to 50 mg/kg/<b>day</b> in divided doses every 8 hours for 10 days; maximum dose: 750 mg/dose (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Giardiasis:</b> Infants, Children, and Adolescents: Oral: 15 to 30 mg/kg/day in divided doses every 8 hours for 5 to 7 days; maximum dose: 250 mg/dose (Bradley 2017; Gardner 2001; Granados 2012; Ross 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Helicobacter pylori</i></b>\n      <b> infection:</b> Children and Adolescents: Oral: 20 mg/kg/<b>day</b> in 2 divided doses for 10 to 14 days in combination with amoxicillin and proton pump inhibitor with or without clarithromycin; maximum daily dose: 1,000 mg/<b>day</b> (NASPGHAN/ESPGHAN [Koletzkol] 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Inflammatory bowel disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Crohn disease, perianal disease; induction:</i> Children and Adolescents: Oral: 7.5 mg/kg/dose 3 times daily for 6 weeks with or without ciprofloxacin; maximum dose: 500 mg/dose (Sandhu 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Ulcerative colitis, pouchitis, persistent:</i> Children and Adolescents: Oral: 20 to 30 mg/kg/<b>day</b> in divided doses 3 times daily for 14 days with or without ciprofloxacin or oral budesonide; maximum dose: 500 mg/dose (Turner 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection:</b> Infants, Children, and Adolescents: IV: 30 to 40 mg/kg/<b>day</b> in divided doses 3 times daily as part of combination therapy; maximum dose: 500 mg/dose (IDSA [Solomkin] 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pelvic inflammatory disease:</b> Adolescents: Oral: 500 mg twice daily for 14 days; give with doxycycline plus a cephalosporin (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis) </b>(ISPD [Warady 2012]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis: Gastrointestinal or genitourinary procedures: Infants, Children, and Adolescents: IV: 10 mg/kg once prior to procedure in combination with cefazolin; Maximum dose: 1,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Infants, Children, and Adolescents: Oral: 10 mg/kg/dose 3 times daily. Maximum daily dose: 1,200 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prophylaxis against sexually transmitted diseases following sexual assault </b>(CDC [Workowski 2015]): Adolescents: Oral: 2,000 mg as a single dose in combination with azithromycin and ceftriaxone</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> Children and Adolescents: IV: 15 mg/kg as a single dose 30 to 60 minutes prior to procedure; maximum single dose: 500 mg (IDSA/ASHP [Bratzler] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Surgical prophylaxis, colorectal:</i> Children and Adolescents: Oral: 15 mg/kg/dose every 3 to 4 hours for 3 doses, starting after mechanical bowel preparation the afternoon and evening before the procedure, with or without additional oral antibiotics and with an appropriate IV antibiotic prophylaxis regimen; maximum dose: 1,000 mg/dose (IDSA/ASHP [Bratzler] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tetanus (Clostridium tetani infection):</b> Infants, Children, and Adolescents: IV, Oral: 30 mg/kg/<b>day</b> in divided doses 4 times daily for 7 to 10 days; maximum daily dose: 4,000 mg/<b>day</b> (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Trichomoniasis; treatment:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;45 kg: 45 mg/kg/<b>day</b> in divided doses 3 times daily for 7 days; maximum daily dose: 2,000 mg/<b>day</b> (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;45 kg and Adolescents: 2,000 mg as a single dose once <b>or </b>500 mg twice daily for 7 days (CDC [Workowski 2015]; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vaginosis, bacterial:</b> Oral: Children &gt;45 kg and Adolescents: 500 mg twice daily for 7 days (CDC [Workowski 2015]; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Amebiasis (acute dysentery):</b> Oral: Immediate release tablets and capsules: 750 mg every 8 hours for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Amebic liver abscess:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release tablets: 500 to 750 mg every 8 hours for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsules: 750 mg every 8 hours for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial vaginosis or vaginitis due to </b>\n      <b>\n        <i>Gardnerella, Mobiluncus</i></b>: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release tablets: 500 mg twice daily for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release tablets: 750 mg once daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Clostridium difficile</b></i>\n      <b>-associated diarrhea (CDAD): Note:</b> Recent guideline recommends converting to oral vancomycin therapy if the patient does not show a clear clinical response after 5 to 7 days of metronidazole therapy (Surawicz 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infection: Oral (immediate release): 500 mg 3 times daily for 10 to 14 days (Cohen 2010; Surawicz 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe complicated infection (no abdominal distention): IV: 500 mg 3 times daily with oral vancomycin for 10 to 14 days (Surawicz 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe complicated infection (with ileus, toxic colitis, and/or abdominal distention): IV: 500 mg 3 times daily with oral and rectal vancomycin for 10 to 14 days (Surawicz 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> Oral (immediate release), IV: 500 mg every 6 hours (maximum: 4,000 mg/day); <b>Note:</b> Initial: 1,000 mg IV loading dose may be administered</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Complicated, community-acquired, mild to moderate (in combination with cephalosporin or fluoroquinolone): IV: 500 mg every 8 to 12 hours or 1,500 mg every 24 hours for 4 to 7 days (provided source controlled) (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Acute diverticulitis, outpatient treatment: Oral (Immediate release): 500 mg every 6 hours; use in combination with a fluoroquinolone (eg, ciprofloxacin) or sulfamethoxazole and trimethoprim (Jacobs 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pelvic inflammatory disease:</b> Oral (immediate release):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Mild to moderately severe:</i> 500 mg twice daily for 14 days (may be added to a combination of a third-generation parenteral cephalosporin and doxycycline) (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>With tubo-ovarian abscess:</i> 500 mg twice daily to complete at least 14 days of therapy (in combination with doxycycline following a parenteral therapy regimen)</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">\n      <b>Surgical prophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> IV 15 mg/kg 1 hour prior to surgical incision; followed by 7.5 mg/kg 6 and 12 hours after initial dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 500 mg within 60 minutes prior to surgical incision in combination with other antibiotics (IDSA/ASHP [Bratzler 2013]). <b>Note:</b> Considered a recommended agent for select procedures other than colorectal surgery (IDSA/ASHP [Bratzler 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral (for colorectal surgical prophylaxis only; immediate release): 1,000 mg every 3 to 4 hours for 3 doses, starting after mechanical bowel preparation the afternoon and evening before the procedure with or without additional oral antibiotics and with an appropriate IV antibiotic prophylaxis regimen (IDSA/ASHP [Bratzler 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Trichomoniasis (index case and sex partner):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> 250 mg every 8 hours for 7 days <b>or</b> 1,000 mg twice daily for 2 doses (on same day) <b>or</b> 2,000 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Alternate dosing:</i> 2,000 mg as a single dose (preferred regimen) <b>or</b> 500 mg twice daily for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsules: 375 mg twice daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild, moderate, or severe impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, decreased renal function does not alter the single-dose pharmacokinetics.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ESRD requiring dialysis: Metronidazole metabolites may accumulate; monitor for adverse events; accumulated metabolites may be rapidly removed by dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis (IHD): If administration cannot be separated from hemodialysis, consider supplemental dose following hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Others have used the following adjustments (Aronoff 2007). <b>Note:</b> Renally adjusted dose recommendations are based on doses of 15 to 30 mg/kg/<b>day</b> divided every 6 to 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &ge;10 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 4 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis: Extensively removed by hemodialysis: 4 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): Extensively removed by peritoneal dialysis: 4 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild, moderate, or severe impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, decreased renal function does not alter the single-dose pharmacokinetics.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ESRD requiring dialysis: Metronidazole metabolites may accumulate; monitor for adverse events; accumulated metabolites may be rapidly removed by dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis (IHD): If administration cannot be separated from hemodialysis, consider supplemental dose following hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (50% to 100%): 500 mg every 8 to 12 hours. <b>Note:</b> Dosing regimen highly dependent on clinical indication (trichomoniasis vs <i>C. difficile</i> colitis) (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of thrice-weekly, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVH/CVVHD/CVVHDF: 500 mg every 6 to 12 hours (or per clinical indication; dosage reduction generally not necessary)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Infants, Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary; use with caution and monitor for adverse events</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe impairment (Child-Pugh class C):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release tablets, injection: Reduce dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release capsules:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Amebiasis: Adults: 375 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Trichomoniasis: Adults: 375 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended release tablets: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: The pharmacokinetics of a single oral 500 mg dose were not altered in patients with cirrhosis; initial dose reduction is therefore not necessary (Daneshmend 1982). In one study of IV metronidazole, patients with alcoholic liver disease (with or without cirrhosis) demonstrated a prolonged elimination half-life (eg, ~18 hours). The authors recommended the dose be reduced accordingly (clearance was reduced by ~62%) and the frequency may be prolonged (eg, every 12 hours instead of every 6 hours) (Lau 1987). In another single IV dose study using metronidazole metabolism to predict hepatic function, patients classified as Child-Pugh class C demonstrated a half-life of ~21.5 hours (Muscar&aacute; 1995).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771210\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flagyl: 375 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 375 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metro: 500 mg (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (100 mL); 5 mg/mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Metronidazole 50: 50 mg/mL (150 mL) [contains saccharin sodium, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Metronidazole 100: 100 mg/mL (150 mL) [contains saccharin sodium, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MetroNIDAZOLE Benzo+SyrSpend: 50 mg/mL (120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flagyl: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flagyl ER: 750 mg [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770972\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26841822\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=metronidazole-systemic-drug-information\" class=\"drug drug_general\">see &quot;Metronidazole (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral solution contains 28 mEq of sodium/gram of metronidazole.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">First-Metronidazole and MetroNIDAZOLE Benzo+SyrSpend oral suspensions are a compounding kits. Refer to manufacturer&rsquo;s labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10529984\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release tablets and capsules: May administer with food to minimize GI upset</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Should be taken on an empty stomach (1 hour before or 2 hours after meals); do not split, chew, or crush.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Administer undiluted (5 mg/mL) by slow intermittent infusion over 30 to 60 minutes. Avoid contact of drug solution with equipment containing aluminum.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771125\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Store at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Protect the tablets from light. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. Avoid excessive heat. Do not refrigerate. Do not remove unit from overwrap until ready for use. Discard unused solution. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10529909\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release formulation:</i> Treatment of susceptible amebiasis (intestinal [dysentery] or liver abscess) (FDA approved in pediatric patients [age not specified] and adults); treatment of susceptible anaerobic bacterial and protozoal infections in the following conditions: Symptomatic and asymptomatic trichomoniasis; skin and skin structure infections, bone and joint infections, CNS infections, endocarditis, gynecological infections, intra-abdominal infections, and respiratory tract (lower) infections; septicemia (FDA approved in adults); has also been used for treatment of peritonitis and treatment of exit site or tunnel infections in patients with peritoneal dialysis catheters </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release formulation:</i> Treatment of bacterial vaginosis (FDA approved in nonpregnant, postmenarchal females)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Treatment of susceptible anaerobic bacteria in the following conditions: Skin and skin structure infections, bone and joint infections, CNS infections, endocarditis, gynecological infections, intra-abdominal infections, and respiratory tract (lower) infections; septicemia, surgical prophylaxis (colorectal) (all indications: FDA approved in adults); has also been used in the prophylaxis of peritonitis in patients with peritoneal catheters undergoing gastrointestinal or genitourinary procedures </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Has also been used for treatment of giardiasis, pelvic inflammatory disease, tetanus, <i>H. pylori</i> and antibiotic-associated pseudomembranous colitis (AAPC) caused by <i>C. difficile</i>, and management of inflammatory bowel disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770967\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MetroNIDAZOLE may be confused with mebendazole, meropenem, metFORMIN, methotrexate, metoclopramide, miconazole</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771039\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, facial edema, flattened T-wave on ECG, flushing, palpitations, peripheral edema, syncope, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Aseptic meningitis, ataxia, brain disease, chills, confusion, convulsions, depression, disulfiram-like reaction (with alcohol), dizziness, drowsiness, dysarthria, headache, hypoesthesia, insomnia, irritability, malaise, metallic taste, numbness, paresthesia, peripheral neuropathy, psychosis, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythematous rash, genital pruritus, hyperhidrosis, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased libido</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, abdominal distress, abdominal pain, anorexia, constipation, decreased appetite, diarrhea, dysgeusia, glossitis, hairy tongue, nausea, pancreatitis (rare), proctitis, stomatitis, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Cystitis, dark urine (rare), dysmenorrhea, dyspareunia, dysuria, urinary incontinence, urinary tract infection, urine abnormality, urine discoloration, vaginal dryness, vaginitis, vulvovaginal candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, eosinophilia, leukopenia, neutropenia (reversible), thrombocytopenia (reversible, rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased liver enzymes, jaundice, severe hepatotoxicity (patients with Cockayne syndrome)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: DRESS syndrome, serum sickness-like reaction (joint pains)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Bacterial infection, candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Inflammation at injection site (IV), injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, muscle spasm, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Abnormal eye movements (saccadic), nystagmus, optic neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Polyuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, flu-like symptoms, nasal congestion, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, lesion (central nervous system, reversible)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771023\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to metronidazole, nitroimidazole derivatives, or any component of the formulation; pregnant patients (first trimester) with trichomoniasis; use of disulfiram within the past 2 weeks; use of alcohol or propylene glycol-containing products during therapy or within 3 days of therapy discontinuation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Active neurological disorders; history of blood dyscrasia; hypothyroidism; hypoadrenalism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771024\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carcinogenic: <b>[US Boxed Warning]: Possibly carcinogenic based on animal data.</b> Reserve use for conditions described in Use; unnecessary use should be avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Severe neurological disturbances, including aseptic meningitis (may occur within hours of a dose), cerebellar symptoms (ataxia, dizziness, dysarthria, nystagmus, saccadic pursuit), convulsive seizures, encephalopathy, optic neuropathy, and peripheral neuropathy (usually symmetric and of sensory type) have been reported. Encephalopathy is associated with widespread lesions on brain MRI; cerebellar toxicity is accompanied by T2 flair lesions within the dentate nuclei seen on MRI. Cerebellar toxicity may occur concurrently with encephalopathy, peripheral neuropathy, or seizures. CNS symptoms and CNS lesions are generally reversible within days to weeks of discontinuation of therapy; peripheral neuropathy symptoms may be prolonged after discontinuation. Monitor for neurologic symptoms and discontinue therapy if any abnormal neurologic symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Candidiasis infection (known or unknown) may be more prominent during metronidazole treatment, antifungal treatment required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Use with caution in patients with or history of blood dyscrasias; agranulocytosis, leukopenia, and neutropenia have occurred. Monitor CBC with differential at baseline, during and after treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cockayne syndrome: Severe hepatotoxicity/acute hepatic failure (has been fatal) has been reported with systemic metronidazole in patients with Cockayne syndrome; onset is rapid after initiation of treatment. Use metronidazole only after risk vs benefit assessment and if there are no appropriate alternatives in patients with Cockayne syndrome. Obtain LFTs prior to treatment initiation, within the first 2 to 3 days of initiation, frequently during therapy, and after treatment is complete. Discontinue treatment if elevated LFTs occur and monitor until LFTs return to baseline.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment due to potential accumulation; dosage adjustment recommended in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment or ESRD due to potential accumulation. Accumulated metabolites may be rapidly removed by hemodialysis; supplemental doses may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage-form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended-release tablets: Do not use in patients with severe hepatic impairment (Child-Pugh class C) unless benefit outweighs risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Use injection with caution in patients with heart failure, edema, or other sodium-retaining states, including corticosteroid treatment due to high sodium content. In patients receiving continuous nasogastric secretion aspiration, sufficient metronidazole may be removed in the aspirate to cause a reduction in serum levels.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Guidelines recommend the use of oral metronidazole for initial treatment of mild to moderate <i>C. difficile</i> infection and the use of oral vancomycin for initial treatment of severe <i>C. difficile</i> infection (with or without IV metronidazole depending on the presence of complications). May treat recurrent mild to moderate infection once with oral metronidazole; avoid use beyond first reoccurrence. (Cohen 2010; Surawicz 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Abdominal cramps, nausea, vomiting, headaches, and flushing have been reported with oral and injectable metronidazole and concomitant alcohol consumption (disulfiram-like reactions); avoid alcoholic beverages or products containing propylene glycol during oral or injectable therapy and for at least 3 days after therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771042\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771043\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16019&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan: MetroNIDAZOLE (Systemic) may increase the serum concentration of Busulfan.  Management: The toxic effects of busulfan may be greatly increased with concomitant use of metronidazole. This combination should probably be avoided when possible.  If these agents must be used together, increased monitoring for busulfan toxicity is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capecitabine: MetroNIDAZOLE (Systemic) may increase serum concentrations of the active metabolite(s) of Capecitabine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbocisteine: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Carbocisteine. Specifically, metronidazole may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: May enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). In particular, the risk for CNS toxicities such as psychosis may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Dronabinol. Specifically, metronidazole may produce severe intolerance to the alcohol contained in the dronabinol oral solution. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Systemic): MetroNIDAZOLE (Systemic) may increase the serum concentration of Fluorouracil (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of MetroNIDAZOLE (Systemic). MetroNIDAZOLE (Systemic) may increase the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Lithium. MetroNIDAZOLE (Systemic) may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Lopinavir. Specifically, the combination of metronidazole and lopinavir/ritonavir solution, which contains 42% alcohol, may result in a disulfiram-like reaction. MetroNIDAZOLE (Systemic) may enhance the arrhythmogenic effect of Lopinavir.  Management: Avoid the concomitant use of lopinavir/ritonavir and metronidazole if possible. If these agents are used concomitantly, monitor for QTc prolongation/arrhythmia and if the lopinavir/ritonavir solution is used, development of a disulfiram-like reaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mebendazole: May enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). Particularly the risk for Stevens-Johnson syndrome or toxic epidermal necrolysis may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: MetroNIDAZOLE (Systemic) may decrease the serum concentration of Mycophenolate. Specifically, metronidazole may decrease concentrations of the active metabolite of mycophenolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: May decrease the serum concentration of MetroNIDAZOLE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of MetroNIDAZOLE (Systemic). MetroNIDAZOLE (Systemic) may increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: May decrease the serum concentration of MetroNIDAZOLE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). Specifically, the combination of ritonavir oral solution or ritonavir soft gelatin capsule, both of which contain alcohol, and metronidazole may result in a disulfiram-like reaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: MetroNIDAZOLE (Systemic) may increase serum concentrations of the active metabolite(s) of Tegafur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Tipranavir. A disulfiram-like reaction may occur due to the alcohol contained in tipranavir capsules. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vecuronium: MetroNIDAZOLE (Systemic) may enhance the neuromuscular-blocking effect of Vecuronium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): MetroNIDAZOLE (Systemic) may increase the serum concentration of Vitamin K Antagonists.  Management: Consider alternatives to concomitant therapy with these agents.  If concomitant therapy cannot be avoided, consider reducing the dose of the vitamin K antagonist and monitor for increased INR/bleeding.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771047\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Peak antibiotic serum concentration lowered and delayed, but total drug absorbed not affected.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771019\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use of metronidazole during the first trimester of pregnancy is contraindicated by the manufacturer for the treatment of trichomoniasis. Metronidazole crosses the placenta. Cleft lip with or without cleft palate has been reported following first trimester exposure to metronidazole; however, most studies have not shown an increased risk of congenital anomalies or other adverse events to the fetus following maternal use during pregnancy. Because metronidazole was carcinogenic in some animal species, concern has been raised whether metronidazole should be used during pregnancy. Available studies have not shown an increased risk of infant cancer following metronidazole exposure during pregnancy; however, the ability to detect a signal for this may have been limited.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Metronidazole pharmacokinetics are similar between pregnant and nonpregnant patients (Amon 1981; Visser 1984; Wang 2011). Bacterial vaginosis has been associated with adverse pregnancy outcomes; metronidazole is recommended for the treatment of symptomatic bacterial vaginosis in pregnant patients (CDC [Workowski 2015]). Vaginal trichomoniasis has been also associated with adverse pregnancy outcomes; use of metronidazole for this indication during the first trimester is contraindicated by the manufacturer; however, some guidelines note treatment can be given at any stage of pregnancy (CDC [Workowski 2015]). Metronidazole may also be used for the treatment of giardiasis in pregnant women (some sources recommend second and third trimester administration only) (Gardner 2001; HHS [OI adult 2015]) and symptomatic amebiasis during pregnancy (HHS [OI adult 2015]; Li 1996). Short courses may be used for the treatment of pouchitis or perianal disease in pregnant women with inflammatory bowel disease (avoid use in the first trimester) (van der Woude 2015).The use of other agents is preferred when treatment is needed during pregnancy for <i>Clostridium difficile</i> (Surawicz 2013) or <i>Helicobacter pylori</i> (Mahadevan 2006). Consult current guidelines for appropriate use in pregnant women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10529985\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor CBC with differential at baseline, during, and after prolonged or repeated courses of therapy. Closely monitor patients with severe hepatic impairment or ESRD for adverse reactions. Observe patients carefully if neurologic symptoms occur and consider discontinuation of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771129\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">After diffusing into the organism, interacts with DNA to cause a loss of helical DNA structure and strand breakage resulting in inhibition of protein synthesis and cell death in susceptible organisms</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771131\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: To bile, seminal fluid, bone, liver, and liver abscesses, lung and vaginal secretions; crosses blood-brain barrier; saliva and CSF concentrations similar to those in plasma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &lt;20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (30% to 60%) to several metabolites including an active hydroxyl metabolite which maintains activity ~30% to 65% of the parent compound (Lamp 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates &lt;7 days (Jager-Roman 1982): Within first week of life, more prolonged than with lower GA: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GA 28 to 30 weeks: 75.3 &plusmn; 16.9 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GA 32 to 35 weeks: 35.4 &plusmn; 1.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GA 36 to 40 weeks: 24.8 &plusmn; 1.6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates &ge;7 days: ~22.5 hours (Upadhyaya 1988) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents: 6 to 10 hours (Lamp 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: Immediate release: 1 to 2 hours; Extended release: ~5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (unchanged drug and metabolites: 60% to 80%; ~20% of total as unchanged drug); feces (6% to 15%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10529989\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium content of 500 mg ready-to-use single dose plastic container: 14 mEq</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771213\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> A metronidazole suspension (50 mg/mL or 100 mg/mL) is commercially available as a compounding kit.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>50 mg/mL Oral Suspension (ASHP Standard Concentration) (ASHP 2017)</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 50 mg/mL oral suspension may be made with tablets and a 1:1 mixture of Ora-Sweet and Ora-Plus. Crush twenty-four 250 mg tablets in a mortar and reduce to a fine powder. Add small portions of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental portions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &quot;shake well&quot;. Stable for 60 days at room temperature or refrigerated (Allen 1996).</p>\n    <div class=\"reference\">Allen LV Jr, Erickson MA 3rd. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. <i>Am J Health Syst Pharm</i>. 1996;53(17):2073-2078.<span class=\"pubmed-id\">8870895</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771212\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Flagyl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">375 mg (50): $717.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (MetroNIDAZOLE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">375 mg (50): $614.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Metro Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/100 mL 0.74% (100 mL): $2.34</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (MetroNIDAZOLE in NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL 0.79% (100 mL): $2.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/100 mL 0.79 (100 mL): $1.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (MetroNIDAZOLE Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (100 mL): $2.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (First-Metronidazole 100 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (150 mL): $127.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (First-Metronidazole 50 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (150 mL): $84.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (MetroNIDAZOLE Benzo+SyrSpend Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (120 mL): $306.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Flagyl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (50): $515.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (50): $920.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (MetroNIDAZOLE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $43.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (500): $345.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961987\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agometrol (TZ);</li>\n      <li>Amevan (EC);</li>\n      <li>Amgyl (LK);</li>\n      <li>Amotrex (BD);</li>\n      <li>Amrizole (QA);</li>\n      <li>Anaemetro (JP);</li>\n      <li>Anaerobex (AT);</li>\n      <li>Anaerobyl (ZW);</li>\n      <li>Anazol (AE, QA);</li>\n      <li>Anerobizol (PH);</li>\n      <li>Antizoal (PH);</li>\n      <li>Ao Ke An (CN);</li>\n      <li>Arilin (DE);</li>\n      <li>Asiazole (TH);</li>\n      <li>Axagyl (PH);</li>\n      <li>Biatron (ID);</li>\n      <li>Camezol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Clont (DE);</li>\n      <li>Clovizole (PH);</li>\n      <li>Dazolin (ID);</li>\n      <li>Deflamon (IT);</li>\n      <li>Dequazol Oral (PE);</li>\n      <li>Dirozyl (BD);</li>\n      <li>Dumozol (AE, BH, CY, JO, KW, SA);</li>\n      <li>Efloran (CZ, UA);</li>\n      <li>Elyzol (FI);</li>\n      <li>Endazole (PH);</li>\n      <li>Entizol (CZ);</li>\n      <li>Farnat (ID);</li>\n      <li>Fentiazol (PY);</li>\n      <li>Fladex (ID);</li>\n      <li>Flagesol (UY);</li>\n      <li>Flagizole (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Flagyl (AR, AU, BB, BE, BG, BH, BR, CH, CL, CO, CU, CY, EC, EG, ES, FR, GB, GR, HK, ID, IE, IL, IN, IS, JO, KR, KW, LB, LK, LU, MT, NL, NO, NZ, PE, PH, PK, PT, QA, RO, RU, SA, SG, SI, TH, TR, TW, VE, VN, ZW);</li>\n      <li>Flahil (UA);</li>\n      <li>Flasinyl (KR);</li>\n      <li>Flazol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Flazole (LV);</li>\n      <li>Fogyl (MY);</li>\n      <li>Frotin (HK, MY, TW);</li>\n      <li>Fu Shu Da (CN);</li>\n      <li>Gynoplix (HK);</li>\n      <li>Helmizol (BR);</li>\n      <li>Klont (MT);</li>\n      <li>Medazol (HR);</li>\n      <li>Metason (LK);</li>\n      <li>Metazol (ZA);</li>\n      <li>Metressa (UA);</li>\n      <li>Metris (ZW);</li>\n      <li>Metrogyl (AU, ET);</li>\n      <li>Metrolag (AE, BF, BH, BJ, CH, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, SA, SC, SD, SL, SN, SY, TN, TW, TZ, UG, YE, ZM, ZW);</li>\n      <li>Metrolex (TH);</li>\n      <li>Metronidazole IV (AU, NZ);</li>\n      <li>Metronide (AU);</li>\n      <li>Metrorex (ET);</li>\n      <li>Metrozin (CO);</li>\n      <li>Molazol (ID);</li>\n      <li>Nalox (AR);</li>\n      <li>Narobic (ZA);</li>\n      <li>Negazole (ET);</li>\n      <li>Nidazole (AE, BH, JO, QA, SA);</li>\n      <li>Nirmet (TH);</li>\n      <li>Normet (ET);</li>\n      <li>Norzol (MT);</li>\n      <li>Novazole (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Patryl (PH);</li>\n      <li>Progyl (ID);</li>\n      <li>Protozol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Protozole (PH);</li>\n      <li>Qualigyl (HK);</li>\n      <li>Qugyl (BD);</li>\n      <li>Rodazid (PH);</li>\n      <li>Ronazol (ID);</li>\n      <li>Sharizole (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Sicabact (ET);</li>\n      <li>Supplin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Trichex (AT);</li>\n      <li>Trizele (KR);</li>\n      <li>Trogiar (ID);</li>\n      <li>Trogyl (ID);</li>\n      <li>Unigo (HK, TH);</li>\n      <li>Vadazol (ID);</li>\n      <li>Vertisal (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Zidoval (AU);</li>\n      <li>Zol (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amon I, Amon K, Franke G, et al. Pharmacokinetics of metronidazole in pregnant women. <i>Chemotherapy</i>. 1981;27(2):73-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/7471904/pubmed\" target=\"_blank\" id=\"7471904\">7471904</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. Drug prescribing in renal failure: dosing guidelines for adults and children. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 23rd ed. American Academy of Pediatrics; 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm</i>. 2013;70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD, Wong B. American College of Gastroenterology guideline on the management of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2007;102(8):1808-1825.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/17608775/pubmed\" target=\"_blank\" id=\"17608775\">17608775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults: 2010 update by the Society for Healthcare Epidemiology of American (SHEA) and the Infectious Diseases Society of America (IDSA). <i>Infect Control Hosp Epidemiol</i>. 2010;31(5):431-455.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/20307191/pubmed\" target=\"_blank\" id=\"20307191\">20307191</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen-Wolkowiez M, Ouellet D, Smith PB, et al. Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. <i>Antimicrob Agents Chemother</i>. 2012;56(4):1828-1837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/22252819/pubmed\" target=\"_blank\" id=\"22252819\">22252819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen-Wolkowiez M, Sampson M, Bloom BT, et al. Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. <i>Pediatr Infect Dis J</i>. 2013;32(9):956-961.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23587979/pubmed\" target=\"_blank\" id=\"23587979\">23587979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daneshmend TK, Homeida M, Kaye CM, Elamin AA, Roberts CJ. Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis. <i>Gut</i>. 1982;23(10):807-813.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/7117899/pubmed\" target=\"_blank\" id=\"7117899\">7117899</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Drugs for Parasitic Infections,&rdquo; <i>Treatment Guidelines From the Medical Letter</i>, 2013, 1(Suppl):e1-31.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Emil S, Laberge JM, Mikhail P, et al. Appendicitis in children: a ten-year update of therapeutic recommendations. <i>J Pediatr Surg</i>. 2003;38(2):236-242.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/12596112/pubmed\" target=\"_blank\" id=\"12596112\">12596112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erickson SH, Oppenheim GL, Smith GH. Metronidazole in breast milk. <i>Obstet Gynecol</i>. 1981;57(1):48-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/7454176 /pubmed\" target=\"_blank\" id=\"7454176 \">7454176 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flagyl capsules (metronidazole) [prescribing information]. New York, NY: Pfizer; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flagyl ER (metronidazole) [prescribing information]. New York, NY: Pfizer; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flagyl (metronidazole) [prescribing information]. New York, NY: Pfizer; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fraser JD, Aguayo P, Leys CM, et al. A complete course of intravenous antibiotics vs a combination of intravenous and oral antibiotics for perforated appendicitis in children: a prospective, randomized trial. <i>J Pediatr Surg</i>. 2010;45(6):1198-1202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/20620320/pubmed\" target=\"_blank\" id=\"20620320\">20620320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardner TB, Hill DR. Treatment of giardiasis. <i>Clin Microbiol Rev</i>. 2001;14(1):114-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/11148005 /pubmed\" target=\"_blank\" id=\"11148005 \">11148005 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Granados CE, Reveiz L, Uribe LG, Criollo CP. Drugs for treating giardiasis. <i>Cochrane Database Syst Rev</i>. 2012;12:CD007787.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23235648/pubmed\" target=\"_blank\" id=\"23235648\">23235648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gray MS, Kane PO, Squires S. Further observations on metronidazole (Flagyl&reg;). <i>Br J Vener Dis</i>. 1961;37:278-279.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/13901320/pubmed\" target=\"_blank\" id=\"13901320\">13901320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heisterberg L, Branebjerg PE. Blood and milk concentrations of metronidazole in mothers and infants. <i>J Perinat Med</i>. 1983; 11(2):114-120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/6854509/pubmed\" target=\"_blank\" id=\"6854509\">6854509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA). April 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf%20\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobs DO. Clinical practice. Diverticulitis. <i>N Engl J Med</i>. 2007;357(20):2057-2066.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/18003962/pubmed\" target=\"_blank\" id=\"18003962\">18003962</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jager-Roman E, Doyle PE, Baird-Lambert J, Cvejic M, Buchanan N. Pharmacokinetics and tissue distribution of metronidazole in the new born infant. <i>J Pediatr</i>. 1982;100(4):651-654.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/7062220/pubmed\" target=\"_blank\" id=\"7062220\">7062220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koletzko S, Jones NL, Goodman KJ, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for <i>Helicobacter pylori</i> infection in children. <i>J Pediatr Gastroenterol Nutr</i>. 2011;53(2):230-243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/21558964/pubmed\" target=\"_blank\" id=\"21558964\">21558964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. <i>Clin Pharmacokinet</i>. 1999;36(5):353-373.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/10384859/pubmed\" target=\"_blank\" id=\"10384859\">10384859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau AH, Evans R, Chang CW, Seligsohn R. Pharmacokinetics of metronidazole in patients with alcoholic liver disease. <i>Antimicrob Agents Chemother</i>. 1987;31(11):1662-1664.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/3435113/pubmed\" target=\"_blank\" id=\"3435113\">3435113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li E, Stanley SL Jr. Protozoa. Amebiasis. <i>Gastroenterol Clin North Am</i>. 1996; 25(3):471-492.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/8863036 /pubmed\" target=\"_blank\" id=\"8863036 \">8863036 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. <i>Gastroenterology</i>. 2006; 131(1):283-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/16831611 /pubmed\" target=\"_blank\" id=\"16831611 \">16831611 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metronidazole injection in sodium chloride [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mottet C, Vader JP, Felley C, et al. Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): results of a multidisciplinary international expert panel-EPACT II. <i>J Crohns Colitis</i>. 2009; 3(4):257-263.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/21172284 /pubmed\" target=\"_blank\" id=\"21172284 \">21172284 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muscar&aacute; MN, Pedrazzoli J Jr, Miranda EL, et al. Plasma hydroxy-metronidazole/metronidazole ratio in patients with liver disease and in healthy volunteers. <i>Br J Clin Pharmacol</i>. 1995;40(5):477-480.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/8703652/pubmed\" target=\"_blank\" id=\"8703652\">8703652</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Passmore CM, McElnay JC, Rainey EA, et al, &quot;Metronidazole Excretion in Human Milk and its Effect on the Suckling Neonate,&quot; <i>Br J Clin Pharmacol</i>, 1988, 26(1):45-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/3203060/pubmed\" target=\"_blank\" id=\"3203060\">3203060</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ross AG, Olds GR, Cripps AW, Farrar JJ, McManus DP. Enteropathogens and chronic illness in returning travelers. <i>N Engl J Med</i>. 2013;368(19):1817-1825.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23656647/pubmed\" target=\"_blank\" id=\"23656647\">23656647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. <i>J Pediatr Gastroenterol Nutr</i>. 2012;55(1):93-108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/22516861/pubmed\" target=\"_blank\" id=\"22516861\">22516861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandhu BK, Fell JM, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. <i>J Pediatr Gastroenterol Nutr</i>. 2010;50(Suppl 1):S1-S13.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schutze GE, Willoughby RE. Committee on Infectious Diseases, American Academy of Pediatrics. <i>Clostridium difficile</i> infection in infants and children. <i>Pediatrics</i>. 2013;131(1):196-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23277317/pubmed\" target=\"_blank\" id=\"23277317\">23277317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2010;50(2):133-164.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    St Peter SD, Little DC, Calkins CM, et al. A simple and more cost-effective antibiotic regimen for perforated appendicitis. <i>J Pediatr Surg</i>. 2006;41(5):1020-1024.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/16677904/pubmed\" target=\"_blank\" id=\"16677904\">16677904</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    St Peter SD, Tsao K, Spilde TL, et al. Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: a prospective randomized trial. <i>J Pediatr Surg</i>. 2008;43(6):981-985.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/18558169/pubmed\" target=\"_blank\" id=\"18558169\">18558169</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of <i>Clostridium difficile</i> infections. <i>Am J Gastroenterol</i>. 2013 Apr;108(4):478-498.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23439232/pubmed\" target=\"_blank\" id=\"23439232\">23439232</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. <i>Clin Infect Dis</i>. 2005;41(8):1159-1166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. <i>J Pediatr Gastroenterol Nutr</i>. 2012;55(3):340-361.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/22773060/pubmed\" target=\"_blank\" id=\"22773060\">22773060</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Upadhyaya P, Bhatnagar V, Basu N. Pharmacokinetics of intravenous metronidazole in neonates. <i>J Pediatr Surg</i>. 1988;23(3):263-265.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/3357144/pubmed\" target=\"_blank\" id=\"3357144\">3357144</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. <i>J Crohns Colitis</i>. 2015;9(2):107-124.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/25602023 /pubmed\" target=\"_blank\" id=\"25602023 \">25602023 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Visser AA and Hundt HK, &quot;The Pharmacokinetics of a Single Intravenous Dose of Metronidazole in Pregnant Patients,&quot; <i>J Antimicrob Chemother</i>, 1984, 13(3):279-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/6725177 /pubmed\" target=\"_blank\" id=\"6725177 \">6725177 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang X, Nanovskaya TN, Zhan Y, et al, &quot;Pharmacokinetics of Metronidazole in Pregnant Patients With Bacterial Vaginosis,&quot; <i>J Matern Fetal Neonatal Med</i>, 2011, 24(3):444-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/20608802/pubmed\" target=\"_blank\" id=\"20608802\">20608802</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;32(Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/22851742 /pubmed\" target=\"_blank\" id=\"22851742 \">22851742 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/23215911</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yardeni D, Kawar B, Siplovich L, et al. Single daily dosing of ceftriaxone and metronidazole is as safe and effective as ampicillin, gentamicin and metronidazole for non-operative management of complicated appendicitis in children. <i>Pediat Therapeut</i>. 2013;3:5.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16019 Version 241.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8770965\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8770969\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8770970\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10529895\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443888\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10529964\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8771210\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8770972\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F26841822\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10529984\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8771125\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10529909\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8770967\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8771039\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8771023\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8771024\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8771042\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8771043\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F8771047\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8771019\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10529985\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8771129\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8771131\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10529989\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F8771213\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8771212\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961987\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16019|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=metronidazole-systemic-drug-information\" class=\"drug drug_general\">Metronidazole (systemic): Drug information</a></li><li><a href=\"topic.htm?path=metronidazole-systemic-patient-drug-information\" class=\"drug drug_patient\">Metronidazole (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}